Twist Bioscience 8-K

PositiveEarningsGuidance raised

DNA Synthesis and Protein Solutions led growth as FY2026 revenue guidance rose; Q4 adjusted EBITDA breakeven target reaffirmed.

Filed 2026-08-03 07:21 ET

Summary

Q3 FY2026 results with raised full-year revenue guidance and Q4 outlook. Revenue grew 23% Y/Y to a record $118.4M, marking 14 consecutive quarters of sequential growth. Twist raised FY2026 revenue guidance by $12M at the midpoint and reiterated its expectation of adjusted EBITDA breakeven in Q4.

Key Figures

Metric Q3 FY2026 Q3 FY2025 Y/Y
Revenue $118.4M $96.1M +23%
DNA Synthesis and Protein Solutions revenue $56.6M $40.8M +39%
NGS Applications revenue $61.8M $55.3M +12%
Operating loss $(36.3)M $(30.1)M n/m
Net loss $(35.1)M $20.4M n/m
Adjusted EBITDA, non-GAAP $(11.3)M $(8.0)M n/m
Diluted EPS $(0.56) $0.33 n/m
  • Gross margin was 52.8%, up 120 bp Q/Q. The prior-year quarter included a $48.8M gain from the Atlas Data Storage spinout, affecting the net income comparison.
  • Cash, cash equivalents and short-term investments totaled approximately $167M at quarter-end.
  • Twist shipped products to approximately 2,650 customers, vs approximately 2,480 a year earlier, and physically shipped approximately 369,000 genes, vs approximately 237,000.

Guidance

Metric Period Guidance Prior Direction
Revenue FY2026 $456M-$457M; ≈21% Y/Y growth $442M-$447M Raised
Gross margin FY2026 Above 52% — —
Revenue Q4 FY2026 ≈$123M-$124M; ≈25% Y/Y growth at midpoint; sequential growth in both segments — —
Adjusted EBITDA, non-GAAP Q4 FY2026 Breakeven — Reaffirmed

Investor Takeaways

  • Q4 revenue against the $123M-$124M outlook and achievement of adjusted EBITDA breakeven are the next near-term measures to watch.
  • FY2026 results will show whether revenue reaches the raised range and gross margin exceeds 52%.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback